Asieris Pharma Launches Women's Unit for Cervical Cancer Breakthrough

Asieris Pharmaceuticals has formed its Women's Health Business Unit, with a particular focus on pioneering therapies in gynecology, notably for cervical cancer. This is a big step forward for women's health. APL-1702, a non-surgical therapy for cervical high-grade squamous intraepithelial lesions, is the unit's flagship endeavor, putting the business at the forefront of revolutionary gynecological care.

This strategic action is consistent with global health programs aimed at treating cervical cancer, such as China's National Program for Women's Development (2021-2030) and the World Health Organization's cervical cancer elimination policy. Asieris Pharmaceuticals hopes to make a substantial contribution to these efforts through the development of APL-1702, which is now in phase III clinical trials and is set to become a groundbreaking non-surgical option for cervical cancer therapy.

Sophia Cao has been selected to oversee this new business unit. She is a seasoned professional with over two decades of expertise in pharmaceutical marketing. Sophia is expected to play a critical role in accomplishing the unit's strategic goals by using her knowledge obtained from significant roles at Organon China, Sanofi Pasteur China, and Eli Lilly China.

Dr. Kevin Pan, Asieris Pharmaceuticals' Founder, Chairman, and CEO, expressed confidence in the development of the Women's Health Business Unit, underlining the company's dedication to its gynecological pipeline, which includes APL-1702. The move cements the company's leadership in women's health in China, with a goal of improving women's health internationally, notably in the prevention and treatment of cervical cancer. APL-1702, the unit's principal asset, aims to meet the clinical demand for effective non-surgical therapies in the field of cervical cancer.